Zacks Investment Research upgraded shares of LivaNova PLC (NASDAQ:LIVN) from a hold rating to a buy rating in a research note issued to investors on Thursday morning. Zacks Investment Research currently has $89.00 target price on the stock.
According to Zacks, “LivaNova PLC is a medical technology company which focuses on providing treatment for cardiovascular diseases and neuromodulation. The Company’s operating units consists of Cardiac Rhythm Management, Cardiac Surgery and Neuromodulation. LivaNova PLC, formerly known as Cyberonics, Inc., is based in London, United Kingdom. “
Several other equities analysts also recently weighed in on the stock. Needham & Company LLC upgraded shares of LivaNova PLC from a hold rating to a buy rating and set a $83.00 target price for the company in a research note on Thursday, September 14th. Piper Jaffray Companies reiterated an overweight rating and issued a $75.00 target price on shares of LivaNova PLC in a research note on Tuesday, September 12th. Jefferies Group LLC initiated coverage on shares of LivaNova PLC in a research note on Friday, September 8th. They issued a buy rating and a $76.00 target price for the company. BidaskClub downgraded shares of LivaNova PLC from a strong-buy rating to a buy rating in a research note on Monday, July 24th. Finally, ValuEngine upgraded shares of LivaNova PLC from a hold rating to a buy rating in a research note on Thursday, November 2nd. One research analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the stock. The company presently has an average rating of Buy and a consensus target price of $77.86.
LivaNova PLC (NASDAQ LIVN) traded down $1.16 on Thursday, hitting $80.26. 197,900 shares of the stock traded hands, compared to its average volume of 412,805. The stock has a market capitalization of $3,869.50, a P/E ratio of 23.13, a price-to-earnings-growth ratio of 2.41 and a beta of 0.52. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.03 and a quick ratio of 1.42. LivaNova PLC has a 52-week low of $40.83 and a 52-week high of $81.85.
LivaNova PLC (NASDAQ:LIVN) last posted its earnings results on Thursday, November 2nd. The company reported $0.93 earnings per share for the quarter, topping the consensus estimate of $0.76 by $0.17. The firm had revenue of $309.70 million during the quarter, compared to the consensus estimate of $301.22 million. LivaNova PLC had a net margin of 4.63% and a return on equity of 9.33%. The company’s revenue was up 4.9% on a year-over-year basis. During the same quarter last year, the company earned $0.78 earnings per share. research analysts expect that LivaNova PLC will post 3.33 earnings per share for the current year.
In other news, Director Daniel Jeffrey Moore sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, September 15th. The shares were sold at an average price of $68.55, for a total value of $68,550.00. Following the completion of the transaction, the director now directly owns 57,296 shares in the company, valued at $3,927,640.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 3,000 shares of company stock valued at $203,890 over the last 90 days. 0.28% of the stock is owned by company insiders.
Hedge funds have recently added to or reduced their stakes in the company. Airain ltd bought a new position in shares of LivaNova PLC in the second quarter valued at approximately $1,449,000. Virginia Retirement Systems ET AL bought a new stake in LivaNova PLC during the second quarter valued at approximately $2,277,000. Hosking Partners LLP lifted its position in LivaNova PLC by 1.6% during the second quarter. Hosking Partners LLP now owns 188,518 shares of the company’s stock valued at $11,539,000 after purchasing an additional 3,048 shares during the last quarter. Redmile Group LLC bought a new stake in LivaNova PLC during the second quarter valued at approximately $12,978,000. Finally, Russell Investments Group Ltd. bought a new stake in LivaNova PLC during the second quarter valued at approximately $957,000. Institutional investors own 81.69% of the company’s stock.
About LivaNova PLC
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for LivaNova PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova PLC and related companies with MarketBeat.com's FREE daily email newsletter.